Clinical Trial Update: Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Ofatumumab in combination with methylprednisolone or with lenalidomide in relapsed/refractory CLL/SLL has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• METHYLPREDNISOLONE (methylprednisolone)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-11-04